CYBN.NE

TORONTO, December 08, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency ("MHRA... Read More...

TORONTO, October 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the launch of the EMBARK Psychedelic Facilitator Training Program.Led by a team of esteemed faculty, the program offers psychedelic clin... Read More...

--The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media--TORONTO, October 19, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progr... Read More...

TORONTO, August 16, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Theresa Firestone has been elected to its board of directors at the Company’s annual and special meeting of shareholders held... Read More...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight market... Read More...

TORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange ("NYSE American"). The Company expects ... Read More...

TORONTO, Jun 22, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug ("IND... Read More...